Articles From: Steiner Leisure Limited Announces Appointment of Stephen Lazarus as Chief Operating Officer and Chief Financial Officer to ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial


2014/12/9
Results from research commissioned by Genpact indicate compliance challenges, limited analytics preparedness, versatile value of shared organizational structures, and selectively strong impact of technology NEW YORK , Dec.
Sign-up for Survey Results: Healthcare Payer COOs Say Advanced Operating Models Can Positively Impact Strategic Challenges investment picks
The Buckle, Inc. (NYSE:BKE) announced that at its quarterly meeting of the Board of Directors, held on December 8, 2014, the Board authorized a $2.77 per share special cash dividend to be paid to shareholders of record at the close of business on January 15, 2015.
Sign-up for The Buckle, Inc. Announces a $2.77 Per Share Special Cash Dividend and a 4.5 Percent Increase in Regular Quarterly Dividend investment picks
2014/12/9
The Securities Arbitration Law Firm of Klayman & Toskes, P.A. ( www.nasd-law.com ) announced today that it is investigating Wells Fargo Advisors (“WFA”), a part of Wells Fargo & Co.
Sign-up for The Securities Arbitration Law Firm of Klayman & Toskes Investigates Wells Fargo Advisors Relating To The Supervision of Michael James Frew investment picks
2014/12/9
The Thai Fund, Inc. (the “Fund”) today declared the following dividend.
Sign-up for The Thai Fund, Inc. Declares a Dividend investment picks
TowerJazz (NASDAQ: TSEM) (TASE: TSEM), the global specialty foundry leader, announced today that Fairchild Semiconductor has started mass production at TowerJazz Panasonic Semiconductor Co.’s (TPSCo’s) fabrication facility in Tonami, Japan.
Sign-up for TowerJazz Announces Successful Transfer of Fairchild Semiconductor’s Discrete Devices to TowerJazz Panasonic Semiconductor’s Japan Fab investment picks
2014/12/9
TravelCenters of America LLC (TravelCenters), operator of the TA® and Petro Stopping Centers® travel center brands, has announced the opening of the first Black Bear Diner restaurant in the TA and Petro network.
Sign-up for TravelCenters of America Opens Black Bear Diner Restaurant at TA Wheeler Ridge, California investment picks
TriQuint Semiconductor, Inc. (NASDAQ: TQNT), a leading RF solutions supplier and technology innovator, announced that it earned continued Trusted Source Category 1A accreditation through 2016 from the Department of Defense (DoD). According to the certification, the accreditation of trust expresses the confidence of the DoD Defense Microelectronics Activity (DMEA) and the National Security Agency’s Trusted Access Program Office (TAPO) that TriQuint will continue to deliver trusted foundry microelectronic goods and services (category 1A) to end users which meet mission critical needs now and into the future.
Sign-up for TriQuint Continues Department of Defense’s Trusted Source Status investment picks
TSYS (NYSE: TSS) announced today its inclusion in the Smart Card Alliance Center of Excellence recognition program.
Sign-up for TSYS Recognized by Smart Card Alliance investment picks
2014/12/9
By Philip van Doorn, MarketWatch Taking holiday sales out of the equation reveals an interesting list of winners You may be up to your ears in reading about Christmas sales.
Sign-up for UPDATE: 10 consumer companies with the best sales growth this year investment picks
2014/12/9
By Brent Kendall WASHINGTON--The U.S. Supreme Court ruled Tuesday that Amazon.com Inc. warehouse workers weren't entitled to pay for the time they spent being screened for theft at the end of their work shifts.
Sign-up for UPDATE: Supreme Court finds Amazon workers not entitled to pay for security screenings investment picks
2014/12/9
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- Tesco PLC shares sank to their lowest level in 14 years Tuesday, leading losses on the FTSE 100, after the supermarket chain issued its fourth profit warning.
Sign-up for UPDATE: Tesco tumbles in London to 14-year low after warning investment picks
The negative technical signals on Tesla Motors' stock (TSLA) keep mounting, after the stock just suffered its first seven-session losing streak since the seven-day stretch ending Jan.
Sign-up for UPDATE: Tesla's stock forms bearish head-and-shoulders pattern as 200-day MA turns down investment picks
2014/12/9
By Anora Mahmudova and Sara Sjolin, MarketWatch Energy, materials stocks sell off NEW YORK (MarketWatch) -- U.S. stocks suffered their biggest one-day slide in nearly seven weeks on Monday as a withering selloff among energy companies, which closely tracked oil's continued price slide, dragged down key benchmark indexes.
Sign-up for UPDATE: The S&P 500 recorded its biggest drop in nearly 7 weeks investment picks
2014/12/9
By Barbara Kollmeyer, MarketWatch Global stocks under pressure, yuan suffers record loss MADRID (MarketWatch) -- U.S. stock futures pointed to a rough start for Wall Street on Tuesday, amid fresh speculation the Federal Reserve may be close to pulling back its pledge to keep rates low, and sagging global markets, with China particularly hard hit.
Sign-up for UPDATE: U.S. stocks: Futures fall on oil worries, Fed rate-hike talk investment picks
Los Angeles, CA, Dec.
Sign-up for VBI to Present at the Equities.com Small-Cap Stars Conference investment picks
2014/12/9
The Western Union Company (NYSE: WU) was recognized today as one of America’s most community-minded companies in The Civic 50 , an annual initiative that identifies companies for their commitment to improve the quality of life in the communities where they do business.
Sign-up for Western Union Recognized in The Civic 50 investment picks
Wake Forest School of Medicine Relocation to Innovation Quarter Anchors Expansion SAN DIEGO , Dec.
Sign-up for Wexford Science & Technology Announces 283,000 Square Foot Expansion of Wake Forest Innovation Quarter investment picks
2014/12/9
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas on behalf of investors who purchased Willbros Group, Inc. (“Willbros” or the “Company”) (NYSE: WG) securities between August 4, 2013 through October 21, 2014.
Sign-up for WG SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Willbros Group Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 29, 2014 investment picks
Yum Brands Inc. shares (YUM) fell 3.6% in after-hours trade Tuesday, after the company's 2015 outlook fell short of analyst estimates.
Sign-up for Yum Brands shares fall as 2015 outlook falls short of estimates investment picks
2014/12/9
Global hiring shows few signs of dramatic uptick in new year MILWAUKEE , Dec.
Sign-up for 2015 to Kick Off with Steady Hiring Expectations in the U.S. According to Latest Manpower Employment Outlook Survey investment picks
Adobe (Nasdaq:ADBE) today announced it will webcast its fourth quarter and fiscal year 2014 earnings conference call to be held later this week.
Sign-up for Adobe to Webcast Q4 and FY14 Earnings Conference Call investment picks
2014/12/8
TAIPEI , Dec.
Sign-up for Advanced Semiconductor Engineering, Inc. Announces Monthly Net Revenues investment picks
NCR Corporation (NYSE: NCR), the global leader in consumer transaction technologies, announced today that Akbank has selected innovative Predictive Services technology from NCR to help increase the availability of its ATMs across Turkey.
Sign-up for Akbank chooses NCR to Further Increase ATM Availability and Enhance Customer Experience investment picks
FORT WORTH, Texas , Dec.
Sign-up for American Airlines Group Reports November Traffic Results investment picks
Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif.
Sign-up for Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3 years for chronic-phase CML (CP-CML) patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options.
Sign-up for ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Steiner Leisure Limited Announces Appointment of Stephen Lazarus as Chief Operating Officer and Chief Financial Officer to ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent